Titan Pharmaceuticals — Investor Presentation (March 2015)
21 slides from Titan Pharmaceuticals's investor presentation, Mar 9, 2015
Slide 1: Corporate Presentation
Corporate Presentation Sunil Bhonsle Mar 2015
Slide 2: Safe Harbor
Safe Harbor The presentation may contain “forward - looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Reference is made in particular to the description of our plans and objectives for future operations, assump
Slide 3: Company Overview
Company Overview Titan Pharmaceuticals specializes in the development of treatments for select chronic diseases utilizing its proprietary ProNeura ™ technology platform • ProNeura : Proprietary Long Term Drug Delivery Platform ▫ Provides non - fluctuating medication levels over periods of six months
Slide 4: Probuphine: The First of its Kind
Probuphine: The First of its Kind Expected to be the first long - acting buprenorphine product on the market for the treatment of opioid dependence • Six month sustained release of buprenorphine • Peak sales potential: $300 - $500 million • U.S. and Canadian partnership with Braeburn Pharmaceuticals
Slide 5: The Epidemic of Opioid Dependence
The Epidemic of Opioid Dependence • Increasingly recognized as a global epidemic by world health authorities • Addiction - a primary, chronic disease of brain reward, motivation, memory and neurobiological circuitry ▫ Cravings, accompanied by lack of impulse control ▫ Abstinence is rarely a successf
Slide 6: Opioid Dependence: Treatment Overview
Opioid Dependence: Treatment Overview Buprenorphine is the Gold Standard in the U.S., Replacing Methadone • Buprenorphine pharmacology makes it an effective, safer and more convenient treatment option ▫ Controls withdrawal symptoms and cravings without inducing opioid euphoria in patients ▫ Convenie
Slide 7: Treatment of Opioid Dependence: Expanding the Market
Sources : IMS Health, Wolters Kluwer Treatment of Opioid Dependence: Expanding the Market • Daily buprenorphine dominates the current market ▫ U.S. sales of daily oral formulations of buprenorphine estimated at $1.5B in 2013 ▫ U.S. buprenorphine prescriptions have exceeded those of methadone since 2
Slide 8: Proprietary ProNeura Technology: Probuphine Implant
EVA polymer Buprenorphine Blended & Extruded Probuphine Proprietary ProNeura Technology: Probuphine Implant • Implant contains 80 mg of buprenorphine HCl , uniformly distributed throughout the ethylene vinyl acetate co - polymer (EVA) matrix • No reservoir, therefore no risk of drug dumping • Follow
Slide 9: Probuphine Clinical Summary
Probuphine Clinical Summary • Six clinical studies completed to date with final Phase 3 study under way ▫ Initial small dose finding study ▫ Two well controlled Phase 3 safety and efficacy studies showing clinical and statistical superiority over placebo and non - inferiority to Suboxone published i
Slide 10: Phase 3 Clinical Study in Progress (PRO-814)
Phase 3 Clinical Study in Progress (Pro - 814) Randomized , double blind and double dummy design. Primary efficacy endpoint based on a non - inferiority comparison of ‘responders’ following six months of treatment with either a dose of four Probuphine implants or treatment with 8 mg or less of an ap
Slide 11: Probuphine Regulatory Timeline
Probuphine Regulatory Timeline • PRO - 814 study completion: Q2, 2015 • Probuphine NDA resubmission: H2, 2015 • FDA Review completion expected within six months 11 Titan Pharmaceuticals Company Overview | Proprietary & Confidential | ©2014 Titan Pharmaceutical, Inc.
Slide 12: Probuphine Value Proposition
Probuphine Value Proposition Probuphine is the first and only potential treatment for opioid dependence that provides non - fluctuating blood levels of buprenorphine around - the - clock for a period of six months 12 Titan Pharmaceuticals Company Overview | Proprietary & Confidential | ©2014 Titan P
Slide 13: Titan: Adding Value Beyond Probuphine
Titan: Adding Value Beyond Probuphine Proprietary ProNeura Technology Platform • Long term drug delivery technology validated through the Probuphine program • Potential for the treatment of select chronic diseases for which low dose long term delivery and stable drug levels may offer advantages over
Slide 14: Parkinson's Disease Overview
Definition Characterized by the loss of dopaminergic neurons which alters activity in the brain region impacting movement and motor function Treatment Treated with drugs designed to replace or mimic dopamine in the brain Following several years of chronic treatment, these drugs lose their benefit an
Slide 15: Treated Population Increasing Worldwide
Treated Population Increasing Worldwide 15 Based on information from Titan and other sources believed to be reliable and prepared exclusively for Titan. Woodside Capita l P artners is not responsible for any use that Titan may make of this material.
Slide 16: Therapeutics Market
Therapeutics Market • As many as one million people in the US affected by Parkinson’s disease • The number expected to almost double by 2030 because of the aging population • About 60,000 newly diagnosed for Parkinson’s disease annually • More than 23,000 die from Parkinson’s disease each year 16 Ti
Slide 17: ProNeura Parkinson's Disease Program Non-clinical Proof of Concept
ProNeura Parkinson’s Disease Program Non - clinical Proof of Concept • Ropinirole ( Requip ® ), a generic dopamine agonist marketed by GSK for PD, was evaluated in a Parkinsonian primate model using ProNeura technology • Results demonstrated: ▫ Sustained plasma ropinirole levels for several months f
Slide 18: ProNeura Parkinson's Disease Program Next Steps
ProNeura Parkinson’s Disease Program Next Steps In consultation with the Scientific Advisory Board: • Optimize implant formulation of ropinirole • Develop non - clinical study plan to support Investigational New Drug (IND) application • Design a proof of concept clinical study • Conduct a pre - IND
Slide 19: Titan Pharmaceuticals Summary
Titan Pharmaceuticals Summary • Titan Pharmaceuticals specializes in the development of treatments for select chronic diseases, utilizing its innovative ProNeura technology platform • Probuphine , a long - acting controlled - release buprenorphine product for opioid dependence; Patient enrolment in
Slide 20: Titan Executive Management
• Marc Rubin, M.D, Executive Chairman and Director ▫ Eight years with Titan Pharmaceuticals. Former Head of Global Research & Development and member of the Board of Management at Bayer Pharma. Executive R&D and commercial responsibilities at GSK for 13 years. Twenty - five years in the pharmaceutica
Slide 21: Thank You
Thank You Sunil Bhonsle Mar 2015
Titan Pharmaceuticals — Investor Presentation (March 2015) on 6ix